oxidopamine has been researched along with Abnormal Movements in 70 studies
Oxidopamine: A neurotransmitter analogue that depletes noradrenergic stores in nerve endings and induces a reduction of dopamine levels in the brain. Its mechanism of action is related to the production of cytolytic free-radicals.
oxidopamine : A benzenetriol that is phenethylamine in which the hydrogens at positions 2, 4, and 5 on the phenyl ring are replaced by hydroxy groups. It occurs naturally in human urine, but is also produced as a metabolite of the drug DOPA (used for the treatment of Parkinson's disease).
| Excerpt | Relevance | Reference |
|---|---|---|
| " To investigate the causative relationship between neuro-inflammation and dyskinesias, we assessed if striatal M1 and M2 microglia numbers correlated with dyskinesia severity and whether the anti-inflammatories, minocycline and indomethacin, reverse these numbers and mitigate against dyskinesia." | 4.31 | The ratio of M1 to M2 microglia in the striatum determines the severity of L-Dopa-induced dyskinesias. ( Egan, T; Kuriakose, A; Rentsch, P; Stayte, S; Vissel, B, 2023) |
| "Long-term levodopa (l-dopa) treatment is associated with the development of l-dopa-induced dyskinesias in the majority of patients with Parkinson disease (PD)." | 3.85 | Striatal activation by optogenetics induces dyskinesias in the 6-hydroxydopamine rat model of Parkinson disease. ( Castela, I; F Hernández, L; Moratalla, R; Obeso, JA; Ruiz-DeDiego, I, 2017) |
| "Dyskinesia is characterized by abnormal involuntary movements (AIMs)." | 1.72 | Agmatine-mediated inhibition of NMDA receptor expression and amelioration of dyskinesia via activation of Nrf2 and suppression of HMGB1/RAGE/TLR4/MYD88/NF-κB signaling cascade in rotenone lesioned rats. ( Azar, YO; Badawi, GA; Ibrahim, SM; Zaki, HF, 2022) |
| "However, unwanted involuntary movements known as L-DOPA-induced dyskinesias (LIDs) develop with prolonged use of this dopamine precursor." | 1.62 | Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease. ( Caulfield, ME; Stancati, JA; Steece-Collier, K, 2021) |
| "The abnormal involuntary movements scale measured L-DOPA and dopamine D1- and D2-receptor agonist-induced dyskinesia." | 1.62 | Effects of pedunculopontine nucleus cholinergic lesion on gait and dyskinesia in hemiparkinsonian rats. ( Bishop, C; Chambers, NE; Clark, SD; Coyle, M; Lanza, K; Saito, C; Sergio, J; Topping, B, 2021) |
| "Abnormal involuntary movements (AIMs) were scored on days 5 and 10." | 1.62 | β‑Lapachone ameliorates L‑DOPA‑induced dyskinesia in a 6‑OHDA‑induced mouse model of Parkinson's disease. ( Choi, YK; Go, J; Kim, KS; Lee, CH; Lee, IB; Park, HY; Ryu, YK, 2021) |
| "Dyskinesia is a serious complication of Parkinson's disease during levodopa (L-DOPA) treatment." | 1.62 | Resveratrol Alleviates Levodopa-Induced Dyskinesia in Rats. ( Fan, HX; Li, JJ; Li, XX; Sheng, S; Zhang, F; Zheng, CQ, 2021) |
| "In contrast, analysis of abnormal involuntary movements (AIMs) induced by L-DOPA treatment of 6-OHDA-lesioned animals yielded two populations: one with mild LID, and the other with severe LID, which are also related to different therapeutic responses." | 1.51 | Severity of Dyskinesia and D3R Signaling Changes Induced by L-DOPA Treatment of Hemiparkinsonian Rats Are Features Inherent to the Treated Subjects. ( Albarrán-Bravo, S; Ávalos-Fuentes, JA; Cortés, H; Erlij, D; Florán, B; Leyva-García, N; Rangel-Barajas, C; Rodriguez-Sánchez, M, 2019) |
| "Dyskinesias are a disabling motor complication that arises with prolonged l-dopa treatment." | 1.46 | Striatal D1 medium spiny neuron activation induces dyskinesias in parkinsonian mice. ( Bordia, T; Perez, XA; Quik, M; Zhang, D, 2017) |
| "Although dopamine replacement therapy with L-DOPA in Parkinson's disease initially reduces motor symptoms, its chronic use often leads to the development of abnormal involuntary movements known as L-DOPA-induced dyskinesia." | 1.43 | Effect of tricyclic antidepressants on L-DOPA-induced dyskinesia and motor improvement in hemi-parkinsonian rats. ( Bishop, C; Conti, MM; Eissa, S; Goldenberg, AA; Kuberka, A; Lindenbach, D; Mohamed, M, 2016) |
| "Levodopa (L-DOPA)-induced dyskinesias (LIDs) represent the major side effect in Parkinson's disease (PD) therapy." | 1.43 | LRRK2 phosphorylation level correlates with abnormal motor behaviour in an experimental model of levodopa-induced dyskinesias. ( Cirnaru, MD; Di Luca, M; Gardoni, F; Mellone, M; Perez-Carrion, M; Piccoli, G; Stanic, J; Zianni, E, 2016) |
| "They also displayed reduced abnormal involuntary movements after apomorphine and quinpirole treatment in the mouse dyskinesia model of Parkinson's disease." | 1.40 | G-protein coupled receptor 6 deficiency alters striatal dopamine and cAMP concentrations and reduces dyskinesia in a mouse model of Parkinson's disease. ( Ferger, B; Hengerer, B; Oeckl, P, 2014) |
| " These results reveal a new interaction between CaMKIIα and D2Rs in striatal neurons which is sensitive to long-term administration of levodopa in PD rats." | 1.40 | Interactions of CaMKII with dopamine D2 receptors: roles in levodopa-induced dyskinesia in 6-hydroxydopamine lesioned Parkinson's rats. ( Liu, Z; Wang, Q; Xie, C; Zhang, S, 2014) |
| "infusion of l-dopa induced abnormal involuntary movements of a similar severity." | 1.39 | Levodopa infusion does not decrease the onset of abnormal involuntary movements in parkinsonian rats. ( Jenner, P; McCreary, AC; Papathanou, M; Rose, S; van der Laan, R, 2013) |
| "These dyskinesias have been severe in a number of patients and represent one of the main obstacles for further development of the cell therapy in PD." | 1.38 | Impact of dopamine versus serotonin cell transplantation for the development of graft-induced dyskinesia in a rat Parkinson model. ( Carlsson, T; Döbrössy, M; García, J; Nikkhah, G; Winkler, C, 2012) |
| "Graft-induced dyskinesias (GIDs), side-effects found in clinical grafting trials for Parkinson's disease (PD), may be associated with the withdrawal of immunosuppression." | 1.35 | The synaptic impact of the host immune response in a parkinsonian allograft rat model: Influence on graft-derived aberrant behaviors. ( Collier, TJ; Freeman, TB; McGuire, SO; Meredith, G; Soderstrom, KE; Sortwell, CE; Steece-Collier, K; Wu, Q, 2008) |
| "Dyskinesias were quantified on days 1 and 22 of levodopa treatment." | 1.35 | Effects of early vs. late initiation of levodopa treatment in hemiparkinsonian rats. ( Aguilar, E; Cortés, R; Marin, C; Mengod, G; Obeso, JA, 2009) |
| "Dyskinesias are a common consequence of dopaminergic therapy in patients with Parkinson's disease." | 1.33 | Focal not widespread grafts induce novel dyskinetic behavior in parkinsonian rats. ( Chu, Y; Collier, TJ; Kordower, JH; Maries, E; Olaru, E; Shannon, K; Sortwell, CE; Steece-Collier, K, 2006) |
| "Levodopa-induced dyskinesias (LIDs) have been associated with a sequence of events that includes pulsatile stimulation of dopamine receptors." | 1.33 | Coadministration of entacapone with levodopa attenuates the severity of dyskinesias in hemiparkinsonian rats. ( Aguilar, E; Marin, C; Obeso, JA, 2006) |
| "Abnormal involuntary movements occurred only in the L-dopa-primed 6-OHDA-lesioned rats that showed after acute l-dopa administration a decrease in firing rate, the highest local field potential power in the theta/alpha band, a consequent oscillatory activity in the same frequency band at the single neuron level and an excessive increase in striatal DA release associated with the lowest level of DA metabolism." | 1.33 | Increased slow oscillatory activity in substantia nigra pars reticulata triggers abnormal involuntary movements in the 6-OHDA-lesioned rat in the presence of excessive extracellular striatal dopamine. ( Bezard, E; Bioulac, B; Boraud, T; Gross, CE; Harnack, D; Klitgaard, H; Kupsch, A; Meissner, W; Morgenstern, R; Ravenscroft, P; Reese, R, 2006) |
| " Our results confirm earlier evidence that the chronic administration of L-DOPA to rats with a unilateral 6-OHDA lesion increases c-fos expression in the STN." | 1.33 | L-DOPA-induced dyskinesia in adult rats with a unilateral 6-OHDA lesion of dopamine neurons is paralleled by increased c-fos gene expression in the subthalamic nucleus. ( Soghomonian, JJ, 2006) |
| "The majority of Parkinson's disease patients undergoing levodopa therapy develop disabling motor complications (dyskinesias) within 10 years of treatment." | 1.32 | Effects of levodopa on endocannabinoid levels in rat basal ganglia: implications for the treatment of levodopa-induced dyskinesias. ( Asbrock, N; Ferrer, B; Giuffrida, A; Kathuria, S; Piomelli, D, 2003) |
| "The characteristics of the abnormal involuntary movements observed in these animals are similar to L-dopa-induced dyskinesias in parkinsonian patients and might be useful as an experimental model for the study of L-dopa-induced dyskinesia." | 1.32 | Bilateral subthalamic nucleus lesion reverses L-dopa-induced motor fluctuations and facilitates dyskinetic movements in hemiparkinsonian rats. ( Bonastre, M; Bové, J; Jiménez, A; Marin, C; Tolosa, E, 2004) |
| "Adenosine A2A receptors are a new target for drug development in Parkinson's disease." | 1.32 | Neuroprotective effect of L-DOPA co-administered with the adenosine A2A receptor agonist CGS 21680 in an animal model of Parkinson's disease. ( Agnati, LF; Ferré, S; Franco, R; Fuxe, K; Hockemeyer, J; Leo, G; Lluis, C; Martínez, E; Vergoni, AV, 2004) |
| "Intermittent L-DOPA treatment induced hypertrophy of the lesioned-side of medial globus pallidus and substantia nigra reticulata of 6-hydroxydopamine-lesioned rats with behavioral sensitization to L-DOPA." | 1.32 | Hypertrophy of medial globus pallidus and substantia nigra reticulata in 6-hydroxydopamine-lesioned rats treated with L-DOPA: implication for L-DOPA-induced dyskinesia in Parkinson's disease. ( Baba, M; Ichinohe, N; Kimura, T; Matsunaga, M; Mori, F; Tomiyama, M; Wakabayashi, K, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 31 (44.29) | 29.6817 |
| 2010's | 29 (41.43) | 24.3611 |
| 2020's | 10 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Caulfield, ME | 1 |
| Stancati, JA | 2 |
| Steece-Collier, K | 4 |
| Azar, YO | 1 |
| Badawi, GA | 1 |
| Zaki, HF | 1 |
| Ibrahim, SM | 1 |
| Castela, I | 4 |
| Casado-Polanco, R | 3 |
| Rubio, YV | 3 |
| da Silva, JA | 3 |
| Marquez, R | 3 |
| Pro, B | 3 |
| Moratalla, R | 7 |
| Redgrave, P | 3 |
| Costa, RM | 3 |
| Obeso, J | 3 |
| Hernandez, LF | 3 |
| Sáez, M | 1 |
| Keifman, E | 1 |
| Alberquilla, S | 1 |
| Coll, C | 1 |
| Reig, R | 1 |
| Murer, MG | 2 |
| Rentsch, P | 1 |
| Egan, T | 1 |
| Kuriakose, A | 1 |
| Stayte, S | 1 |
| Vissel, B | 1 |
| Albarrán-Bravo, S | 1 |
| Ávalos-Fuentes, JA | 1 |
| Cortés, H | 1 |
| Rodriguez-Sánchez, M | 1 |
| Leyva-García, N | 1 |
| Rangel-Barajas, C | 1 |
| Erlij, D | 1 |
| Florán, B | 1 |
| Mercado, NM | 1 |
| Sortwell, CE | 3 |
| Mueller, RL | 1 |
| Boezwinkle, SA | 1 |
| Duffy, MF | 1 |
| Fischer, DL | 1 |
| Sandoval, IM | 1 |
| Manfredsson, FP | 1 |
| Collier, TJ | 3 |
| Chen, J | 1 |
| Wang, Q | 2 |
| Li, N | 1 |
| Huang, S | 1 |
| Li, M | 1 |
| Cai, J | 1 |
| Wang, Y | 1 |
| Wen, H | 1 |
| Lv, S | 1 |
| Wang, N | 1 |
| Wang, J | 2 |
| Luo, F | 1 |
| Zhang, W | 1 |
| Chambers, NE | 1 |
| Coyle, M | 1 |
| Sergio, J | 1 |
| Lanza, K | 1 |
| Saito, C | 1 |
| Topping, B | 1 |
| Clark, SD | 1 |
| Bishop, C | 4 |
| Ryu, YK | 1 |
| Park, HY | 1 |
| Go, J | 1 |
| Lee, IB | 1 |
| Choi, YK | 1 |
| Lee, CH | 1 |
| Kim, KS | 1 |
| Zheng, CQ | 1 |
| Fan, HX | 1 |
| Li, XX | 1 |
| Li, JJ | 1 |
| Sheng, S | 1 |
| Zhang, F | 1 |
| Crabbé, M | 1 |
| Van der Perren, A | 1 |
| Weerasekera, A | 1 |
| Himmelreich, U | 1 |
| Baekelandt, V | 1 |
| Van Laere, K | 1 |
| Casteels, C | 1 |
| Gomez, G | 1 |
| Escande, MV | 1 |
| Suarez, LM | 1 |
| Rela, L | 1 |
| Belforte, JE | 1 |
| Gershanik, OS | 1 |
| Taravini, IRE | 1 |
| Tronci, E | 1 |
| Fidalgo, C | 1 |
| Zianni, E | 2 |
| Collu, M | 1 |
| Stancampiano, R | 1 |
| Morelli, M | 1 |
| Gardoni, F | 2 |
| Carta, M | 1 |
| Oeckl, P | 1 |
| Hengerer, B | 1 |
| Ferger, B | 1 |
| Papathanou, M | 2 |
| Jenner, P | 3 |
| Iravani, M | 1 |
| Jackson, M | 1 |
| Stockwell, K | 1 |
| Strang, I | 1 |
| Zeng, BY | 1 |
| McCreary, AC | 2 |
| Rose, S | 2 |
| Zhang, S | 1 |
| Xie, C | 1 |
| Liu, Z | 1 |
| Xie, CL | 1 |
| Wang, WW | 1 |
| Zhang, SF | 1 |
| Yuan, ML | 1 |
| Che, JY | 1 |
| Gan, J | 1 |
| Song, L | 1 |
| Yuan, WE | 1 |
| Liu, ZG | 1 |
| Urs, NM | 1 |
| Bido, S | 1 |
| Peterson, SM | 1 |
| Daigle, TL | 1 |
| Bass, CE | 1 |
| Gainetdinov, RR | 1 |
| Bezard, E | 4 |
| Caron, MG | 1 |
| Conti, MM | 1 |
| Goldenberg, AA | 1 |
| Kuberka, A | 1 |
| Mohamed, M | 1 |
| Eissa, S | 1 |
| Lindenbach, D | 1 |
| Stanic, J | 1 |
| Mellone, M | 1 |
| Cirnaru, MD | 1 |
| Perez-Carrion, M | 1 |
| Di Luca, M | 1 |
| Piccoli, G | 1 |
| Dahl, R | 1 |
| Perez, XA | 1 |
| Zhang, D | 1 |
| Bordia, T | 1 |
| Quik, M | 1 |
| F Hernández, L | 1 |
| Ruiz-DeDiego, I | 1 |
| Obeso, JA | 3 |
| Soderstrom, KE | 1 |
| Meredith, G | 1 |
| Freeman, TB | 1 |
| McGuire, SO | 1 |
| Wu, Q | 1 |
| Lane, EL | 4 |
| Soulet, D | 1 |
| Vercammen, L | 1 |
| Cenci, MA | 4 |
| Brundin, P | 2 |
| Mo, J | 1 |
| Zhang, H | 1 |
| Yu, LP | 1 |
| Sun, PH | 1 |
| Jin, GZ | 1 |
| Zhen, X | 1 |
| Schmidt, WJ | 1 |
| Lebsanft, H | 1 |
| Heindl, M | 1 |
| Gerlach, M | 1 |
| Gruenblatt, E | 1 |
| Riederer, P | 1 |
| Mayerhofer, A | 1 |
| Scheller, DK | 1 |
| Yuan, CX | 1 |
| Ye, Q | 1 |
| Zhang, Y | 1 |
| Yuan, CG | 1 |
| Morgese, MG | 1 |
| Cassano, T | 1 |
| Gaetani, S | 1 |
| Macheda, T | 2 |
| Laconca, L | 1 |
| Dipasquale, P | 1 |
| Ferraro, L | 1 |
| Antonelli, T | 1 |
| Cuomo, V | 1 |
| Giuffrida, A | 3 |
| Santini, E | 1 |
| Alcacer, C | 1 |
| Cacciatore, S | 1 |
| Heiman, M | 1 |
| Hervé, D | 1 |
| Greengard, P | 1 |
| Girault, JA | 1 |
| Valjent, E | 1 |
| Fisone, G | 1 |
| Ikeda, K | 1 |
| Yoshikawa, S | 1 |
| Kurokawa, T | 1 |
| Yuzawa, N | 1 |
| Nakao, K | 1 |
| Mochizuki, H | 2 |
| Marin, C | 4 |
| Aguilar, E | 3 |
| Mengod, G | 2 |
| Cortés, R | 2 |
| Akita, H | 1 |
| Honda, Y | 1 |
| Ogata, M | 1 |
| Noda, K | 1 |
| Saji, M | 1 |
| Ahmed, MR | 1 |
| Berthet, A | 1 |
| Bychkov, E | 1 |
| Porras, G | 2 |
| Li, Q | 2 |
| Bioulac, BH | 2 |
| Carl, YT | 1 |
| Bloch, B | 1 |
| Kook, S | 1 |
| Aubert, I | 1 |
| Dovero, S | 1 |
| Doudnikoff, E | 1 |
| Gurevich, VV | 1 |
| Gurevich, EV | 1 |
| Cao, X | 1 |
| Yasuda, T | 1 |
| Uthayathas, S | 1 |
| Watts, RL | 1 |
| Mouradian, MM | 1 |
| Papa, SM | 1 |
| Wree, A | 1 |
| Mix, E | 1 |
| Hawlitschka, A | 1 |
| Antipova, V | 1 |
| Witt, M | 1 |
| Schmitt, O | 1 |
| Benecke, R | 1 |
| McFarland, K | 1 |
| Price, DL | 1 |
| Bonhaus, DW | 1 |
| García, J | 2 |
| Carlsson, T | 2 |
| Döbrössy, M | 2 |
| Nikkhah, G | 2 |
| Winkler, C | 2 |
| Ohlin, KE | 1 |
| Sebastianutto, I | 1 |
| Adkins, CE | 1 |
| Lundblad, C | 1 |
| Lockman, PR | 1 |
| Abuirmeileh, A | 1 |
| Harkavyi, A | 1 |
| Rampersaud, N | 1 |
| Lever, R | 1 |
| Tadross, JA | 1 |
| Bloom, SR | 1 |
| Whitton, PS | 1 |
| Wang, A | 1 |
| Wang, L | 1 |
| Sun, K | 1 |
| Liu, W | 1 |
| Sha, C | 1 |
| Li, Y | 1 |
| Paquette, MA | 1 |
| Martinez, AA | 1 |
| Meshul, CK | 1 |
| Johnson, SW | 1 |
| Berger, SP | 1 |
| van der Laan, R | 1 |
| Neto, SC | 1 |
| Salti, A | 1 |
| Puschban, Z | 1 |
| Stefanova, N | 1 |
| Nat, R | 1 |
| Dechant, G | 1 |
| Wenning, GK | 1 |
| Mura, A | 1 |
| Mintz, M | 1 |
| Feldon, J | 1 |
| Klintenberg, R | 1 |
| Arts, J | 1 |
| Jongsma, M | 1 |
| Wikström, H | 1 |
| Gunne, L | 1 |
| Andrén, PE | 1 |
| Ferrer, B | 1 |
| Asbrock, N | 1 |
| Kathuria, S | 1 |
| Piomelli, D | 1 |
| Jiménez, A | 1 |
| Tolosa, E | 1 |
| Bonastre, M | 1 |
| Bové, J | 2 |
| Paillé, V | 1 |
| Brachet, P | 1 |
| Damier, P | 1 |
| Agnati, LF | 1 |
| Leo, G | 1 |
| Vergoni, AV | 1 |
| Martínez, E | 1 |
| Hockemeyer, J | 1 |
| Lluis, C | 1 |
| Franco, R | 1 |
| Fuxe, K | 1 |
| Ferré, S | 1 |
| Tomiyama, M | 1 |
| Mori, F | 1 |
| Kimura, T | 1 |
| Ichinohe, N | 1 |
| Wakabayashi, K | 1 |
| Matsunaga, M | 1 |
| Baba, M | 1 |
| Cheetham, SC | 1 |
| Nash, JE | 1 |
| Johnston, TH | 1 |
| Collingridge, GL | 1 |
| Garner, CC | 1 |
| Brotchie, JM | 1 |
| Maries, E | 1 |
| Kordower, JH | 1 |
| Chu, Y | 1 |
| Olaru, E | 1 |
| Shannon, K | 1 |
| Pavón, N | 1 |
| Martín, AB | 1 |
| Mendialdua, A | 1 |
| Taylor, JL | 1 |
| Ullrich, T | 1 |
| Rice, KC | 1 |
| Walker, PD | 1 |
| Chaturvedi, RK | 1 |
| Shukla, S | 1 |
| Seth, K | 1 |
| Chauhan, S | 1 |
| Sinha, C | 1 |
| Shukla, Y | 1 |
| Agrawal, AK | 1 |
| Serrats, J | 1 |
| Meissner, W | 1 |
| Ravenscroft, P | 1 |
| Reese, R | 1 |
| Harnack, D | 1 |
| Morgenstern, R | 1 |
| Kupsch, A | 1 |
| Klitgaard, H | 1 |
| Bioulac, B | 1 |
| Gross, CE | 1 |
| Boraud, T | 1 |
| Dekundy, A | 1 |
| Pietraszek, M | 1 |
| Schaefer, D | 1 |
| Danysz, W | 1 |
| Soghomonian, JJ | 1 |
| Gubellini, P | 1 |
| Eusebio, A | 1 |
| Oueslati, A | 1 |
| Melon, C | 1 |
| Kerkerian-Le Goff, L | 1 |
| Salin, P | 1 |
| Han, F | 1 |
| Wang, H | 1 |
| Dupre, KB | 1 |
| Eskow, KL | 1 |
| Negron, G | 1 |
| Gold, SJ | 1 |
| Hoang, CV | 1 |
| Potts, BW | 1 |
| Pioli, E | 1 |
| Kim, KW | 1 |
| Nadjar, A | 1 |
| Qin, C | 1 |
| LaHoste, GJ | 1 |
| Waugh, JL | 1 |
| Gurevich, E | 1 |
| Neve, RL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Preventing Levodopa Induced Dyskinesia in Parkinson?s Disease With Statins[NCT04064294] | 120 participants (Anticipated) | Observational | 2019-06-01 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for oxidopamine and Abnormal Movements
| Article | Year |
|---|---|
Clinical and experimental experiences of graft-induced dyskinesia.
Topics: Animals; Brain Tissue Transplantation; Disease Models, Animal; Dyskinesias; Humans; Oxidopamine; Par | 2011 |
69 other studies available for oxidopamine and Abnormal Movements
| Article | Year |
|---|---|
Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease.
Topics: Animals; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Dyskinesias; Levodopa; Oxidopam | 2021 |
Agmatine-mediated inhibition of NMDA receptor expression and amelioration of dyskinesia via activation of Nrf2 and suppression of HMGB1/RAGE/TLR4/MYD88/NF-κB signaling cascade in rotenone lesioned rats.
Topics: Agmatine; Animals; Antioxidants; Dyskinesias; HMGB1 Protein; Levodopa; Myeloid Differentiation Facto | 2022 |
Selective activation of striatal indirect pathway suppresses levodopa induced-dyskinesias.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesias; Levod | 2023 |
Selective activation of striatal indirect pathway suppresses levodopa induced-dyskinesias.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesias; Levod | 2023 |
Selective activation of striatal indirect pathway suppresses levodopa induced-dyskinesias.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesias; Levod | 2023 |
Selective activation of striatal indirect pathway suppresses levodopa induced-dyskinesias.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesias; Levod | 2023 |
Selective activation of striatal indirect pathway suppresses levodopa induced-dyskinesias.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesias; Levod | 2023 |
Selective activation of striatal indirect pathway suppresses levodopa induced-dyskinesias.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesias; Levod | 2023 |
Selective activation of striatal indirect pathway suppresses levodopa induced-dyskinesias.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesias; Levod | 2023 |
Selective activation of striatal indirect pathway suppresses levodopa induced-dyskinesias.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesias; Levod | 2023 |
Selective activation of striatal indirect pathway suppresses levodopa induced-dyskinesias.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesias; Levod | 2023 |
D2 dopamine receptors and the striatopallidal pathway modulate L-DOPA-induced dyskinesia in the mouse.
Topics: Animals; Dopamine Agonists; Dyskinesias; Levodopa; Mice; Oxidopamine; Quinpirole; Receptors, Dopamin | 2023 |
The ratio of M1 to M2 microglia in the striatum determines the severity of L-Dopa-induced dyskinesias.
Topics: Animals; Anti-Inflammatory Agents; Antiparkinson Agents; Corpus Striatum; Dyskinesias; Indomethacin; | 2023 |
Severity of Dyskinesia and D3R Signaling Changes Induced by L-DOPA Treatment of Hemiparkinsonian Rats Are Features Inherent to the Treated Subjects.
Topics: Animals; Cyclic AMP; Dopamine; Dopaminergic Neurons; Dyskinesias; Levodopa; Male; Medial Forebrain B | 2019 |
The BDNF Val66Met polymorphism (rs6265) enhances dopamine neuron graft efficacy and side-effect liability in rs6265 knock-in rats.
Topics: Animals; Antiparkinson Agents; Brain-Derived Neurotrophic Factor; Cell Transplantation; Dopaminergic | 2021 |
Dyskinesia is Closely Associated with Synchronization of Theta Oscillatory Activity Between the Substantia Nigra Pars Reticulata and Motor Cortex in the Off L-dopa State in Rats.
Topics: Aged; Animals; Antiparkinson Agents; Dyskinesias; Humans; Levodopa; Motor Cortex; Oxidopamine; Pars | 2021 |
Effects of pedunculopontine nucleus cholinergic lesion on gait and dyskinesia in hemiparkinsonian rats.
Topics: Animals; Cholinergic Agents; Disease Models, Animal; Dyskinesias; Gait; Gait Disorders, Neurologic; | 2021 |
β‑Lapachone ameliorates L‑DOPA‑induced dyskinesia in a 6‑OHDA‑induced mouse model of Parkinson's disease.
Topics: Animals; Dyskinesias; Levodopa; Male; Mice; Naphthoquinones; Oxidopamine; Parkinson Disease, Seconda | 2021 |
Resveratrol Alleviates Levodopa-Induced Dyskinesia in Rats.
Topics: Animals; Biomarkers; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Dyskinesias; Levodopa; | 2021 |
Altered mGluR5 binding potential and glutamine concentration in the 6-OHDA rat model of acute Parkinson's disease and levodopa-induced dyskinesia.
Topics: Acute Disease; Animals; Cerebral Cortex; Disease Models, Animal; Dyskinesias; Female; Glutamine; Lev | 2018 |
Changes in Dendritic Spine Density and Inhibitory Perisomatic Connectivity onto Medium Spiny Neurons in L-Dopa-Induced Dyskinesia.
Topics: Animals; Corpus Striatum; Cytoskeletal Proteins; Dendritic Spines; Dyskinesias; Female; Interneurons | 2019 |
Effect of memantine on L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson's disease.
Topics: Amantadine; Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesias; Excitatory Amino Aci | 2014 |
G-protein coupled receptor 6 deficiency alters striatal dopamine and cAMP concentrations and reduces dyskinesia in a mouse model of Parkinson's disease.
Topics: Adrenergic Agents; Animals; Anti-Dyskinesia Agents; Corpus Striatum; Cyclic AMP; Disease Models, Ani | 2014 |
The H3 receptor agonist immepip does not affect l-dopa-induced abnormal involuntary movements in 6-OHDA-lesioned rats.
Topics: Animals; Dyskinesia, Drug-Induced; Dyskinesias; Histamine Agonists; Imidazoles; Levodopa; Male; Oxid | 2014 |
Interactions of CaMKII with dopamine D2 receptors: roles in levodopa-induced dyskinesia in 6-hydroxydopamine lesioned Parkinson's rats.
Topics: Amino Acid Motifs; Animals; Binding Sites; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Corpu | 2014 |
Levodopa/benserazide microsphere (LBM) prevents L-dopa induced dyskinesia by inactivation of the DR1/PKA/P-tau pathway in 6-OHDA-lesioned Parkinson's rats.
Topics: Adrenergic Agents; Animals; Benserazide; Blotting, Western; Corpus Striatum; Cyclic AMP-Dependent Pr | 2014 |
Targeting β-arrestin2 in the treatment of L-DOPA-induced dyskinesia in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Arrestins; Behavior, Animal; beta-Arrestins; | 2015 |
Effect of tricyclic antidepressants on L-DOPA-induced dyskinesia and motor improvement in hemi-parkinsonian rats.
Topics: Animals; Antidepressive Agents, Tricyclic; Corpus Striatum; Dopamine; Dyskinesias; Levodopa; Male; N | 2016 |
LRRK2 phosphorylation level correlates with abnormal motor behaviour in an experimental model of levodopa-induced dyskinesias.
Topics: Animals; Disease Models, Animal; Dyskinesias; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; | 2016 |
A new target for Parkinson's disease: Small molecule SERCA activator CDN1163 ameliorates dyskinesia in 6-OHDA-lesioned rats.
Topics: Aminoquinolines; Animals; Benzamides; Calcium; Cell Death; Drug Discovery; Dyskinesias; Endoplasmic | 2017 |
Striatal D1 medium spiny neuron activation induces dyskinesias in parkinsonian mice.
Topics: Animals; Antiparkinson Agents; Channelrhodopsins; Cocaine; Corpus Striatum; Disease Models, Animal; | 2017 |
Striatal activation by optogenetics induces dyskinesias in the 6-hydroxydopamine rat model of Parkinson disease.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Brain; Channelrhodopsins; Corpus Striatum; Disease | 2017 |
The synaptic impact of the host immune response in a parkinsonian allograft rat model: Influence on graft-derived aberrant behaviors.
Topics: Adrenergic Agents; Amphetamine; Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Ani | 2008 |
Neuroinflammation in the generation of post-transplantation dyskinesia in Parkinson's disease.
Topics: Adrenergic Agents; Amphetamine; Analgesics, Non-Narcotic; Analysis of Variance; Animals; Antiparkins | 2008 |
L-stepholidine reduced L-DOPA-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Analysis of Variance; Animals; Antiparkinson Agents; Antipsy | 2010 |
Continuous versus pulsatile administration of rotigotine in 6-OHDA-lesioned rats: contralateral rotations and abnormal involuntary movements.
Topics: Adrenergic Agents; Animals; Dopamine Agonists; Dyskinesia, Drug-Induced; Dyskinesias; Male; Oxidopam | 2008 |
[Effects of traditional Chinese herbal medicine on the neurobehavioral manifestations and the activity of dopamine D2 receptor in corpora striatum of rats with levodopa-induced dyskinesias].
Topics: Animals; Benserazide; Corpus Striatum; Drugs, Chinese Herbal; Dyskinesias; Levodopa; Male; Oxidopami | 2008 |
Neurochemical changes in the striatum of dyskinetic rats after administration of the cannabinoid agonist WIN55,212-2.
Topics: Amphetamine; Animals; Benzoxazines; Calcium Channel Blockers; Cannabinoids; Corpus Striatum; Dopamin | 2009 |
L-DOPA activates ERK signaling and phosphorylates histone H3 in the striatonigral medium spiny neurons of hemiparkinsonian mice.
Topics: Animals; Antiparkinson Agents; Blotting, Western; Dyskinesias; Extracellular Signal-Regulated MAP Ki | 2009 |
Amphetamine-induced abnormal movements occur independently of both transplant- and host-derived serotonin innervation following neural grafting in a rat model of Parkinson's disease.
Topics: 5,7-Dihydroxytryptamine; Adrenergic Agents; Amphetamine; Animals; Antiparkinson Agents; Behavior, An | 2009 |
TRK-820, a selective kappa opioid receptor agonist, could effectively ameliorate L-DOPA-induced dyskinesia symptoms in a rat model of Parkinson's disease.
Topics: Amantadine; Animals; Behavior, Animal; Disease Models, Animal; Dyskinesias; Extracellular Space; Lev | 2009 |
Effects of early vs. late initiation of levodopa treatment in hemiparkinsonian rats.
Topics: Animals; Corpus Striatum; Dopamine Plasma Membrane Transport Proteins; Dynorphins; Dyskinesias; Elec | 2009 |
Activation of the NMDA receptor involved in the alleviating after-effect of repeated stimulation of the subthalamic nucleus on motor deficits in hemiparkinsonian rats.
Topics: Animals; Deep Brain Stimulation; Dizocilpine Maleate; Dyskinesias; Excitatory Amino Acid Antagonists | 2010 |
Lentiviral overexpression of GRK6 alleviates L-dopa-induced dyskinesia in experimental Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Dose- | 2010 |
Striatal overexpression of DeltaFosB reproduces chronic levodopa-induced involuntary movements.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Drug Administration Schedule; Dyskinesias; Functio | 2010 |
Intrastriatal botulinum toxin abolishes pathologic rotational behaviour and induces axonal varicosities in the 6-OHDA rat model of Parkinson's disease.
Topics: Animals; Axons; Botulinum Toxins, Type A; Corpus Striatum; Disease Models, Animal; Dyskinesias; Grow | 2011 |
Pimavanserin, a 5-HT2A inverse agonist, reverses psychosis-like behaviors in a rodent model of Parkinson's disease.
Topics: Amphetamine; Amphetamines; Animals; Antipsychotic Agents; Behavior, Animal; Central Nervous System S | 2011 |
Extent of pre-operative L-DOPA-induced dyskinesia predicts the severity of graft-induced dyskinesia after fetal dopamine cell transplantation.
Topics: Amphetamines; Animals; Apomorphine; Corpus Striatum; Disease Models, Animal; Dopamine Agents; Dopami | 2011 |
Impact of L-DOPA treatment on regional cerebral blood flow and metabolism in the basal ganglia in a rat model of Parkinson's disease.
Topics: Algorithms; Animals; Antiparkinson Agents; Autoradiography; Basal Ganglia; Behavior, Animal; Bensera | 2012 |
Exendin-4 treatment enhances L-DOPA evoked release of striatal dopamine and decreases dyskinetic movements in the 6-hydoxydopamine lesioned rat.
Topics: Animals; Behavior, Animal; Corpus Striatum; Dopamine; Drug Synergism; Dyskinesias; Exenatide; Glucag | 2012 |
Preparation of rotigotine-loaded microspheres and their combination use with L-DOPA to modify dyskinesias in 6-OHDA-lesioned rats.
Topics: Animals; Dopamine Agonists; Drug Carriers; Drug Therapy, Combination; Dyskinesias; Levodopa; Male; M | 2012 |
Impact of dopamine versus serotonin cell transplantation for the development of graft-induced dyskinesia in a rat Parkinson model.
Topics: Adrenergic Agents; Amphetamines; Analysis of Variance; Animals; Antiparkinson Agents; Cell Transplan | 2012 |
Anti-dyskinetic mechanisms of amantadine and dextromethorphan in the 6-OHDA rat model of Parkinson's disease: role of NMDA vs. 5-HT1A receptors.
Topics: Amantadine; Animals; Antiparkinson Agents; Cycloserine; Dextromethorphan; Dopamine Agents; Dyskinesi | 2012 |
Levodopa infusion does not decrease the onset of abnormal involuntary movements in parkinsonian rats.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Area Under Curve; Disease Models, Animal; Dyskines | 2013 |
Cell fate analysis of embryonic ventral mesencephalic grafts in the 6-OHDA model of Parkinson's disease.
Topics: Adrenergic Agents; Amphetamines; Animals; Cell Transplantation; Chickens; Dyskinesias; Gene Expressi | 2012 |
Behavioral and anatomical effects of long-term L-dihydroxyphenylalanine (L-DOPA) administration in rats with unilateral lesions of the nigrostriatal system.
Topics: Animals; Corpus Striatum; Dyskinesias; Genes, fos; Injections, Intraventricular; Levodopa; Male; Oxi | 2002 |
Motor effects of a dopamine stabilizer (GMC1111) in primate models of Parkinson and hemiparkinsonism.
Topics: Animals; Callithrix; Disease Models, Animal; Dopamine; Dyskinesias; Female; Indans; Male; Motor Acti | 2003 |
Effects of levodopa on endocannabinoid levels in rat basal ganglia: implications for the treatment of levodopa-induced dyskinesias.
Topics: Animals; Antiparkinson Agents; Basal Ganglia; Behavior, Animal; Benzazepines; Benzoxazines; Brain Ch | 2003 |
Bilateral subthalamic nucleus lesion reverses L-dopa-induced motor fluctuations and facilitates dyskinetic movements in hemiparkinsonian rats.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Dose-Response Relationship, | 2004 |
Role of nigral lesion in the genesis of dyskinesias in a rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Cell Count; Dyskinesias; Immunohistochemistry; Levo | 2004 |
Neuroprotective effect of L-DOPA co-administered with the adenosine A2A receptor agonist CGS 21680 in an animal model of Parkinson's disease.
Topics: Adenosine; Adenosine A2 Receptor Agonists; Analysis of Variance; Animals; Antiparkinson Agents; Apom | 2004 |
Hypertrophy of medial globus pallidus and substantia nigra reticulata in 6-hydroxydopamine-lesioned rats treated with L-DOPA: implication for L-DOPA-induced dyskinesia in Parkinson's disease.
Topics: Animals; Dyskinesias; Globus Pallidus; Hypertrophy; Levodopa; Male; Oxidopamine; Parkinson Disease; | 2004 |
Repeated administration of the monoamine reuptake inhibitor BTS 74 398 induces ipsilateral circling in the 6-hydroxydopamine lesioned rat without sensitizing motor behaviours.
Topics: Adrenergic Agents; Animals; Chlorobenzenes; Corpus Striatum; Cyclobutanes; Dopamine Agents; Dose-Res | 2005 |
Subcellular redistribution of the synapse-associated proteins PSD-95 and SAP97 in animal models of Parkinson's disease and L-DOPA-induced dyskinesia.
Topics: Adaptor Proteins, Signal Transducing; Animals; Behavior, Animal; Brain; Brain Chemistry; Cell Membra | 2005 |
Focal not widespread grafts induce novel dyskinetic behavior in parkinsonian rats.
Topics: Animals; Behavior, Animal; Brain Tissue Transplantation; Corpus Striatum; Disease Models, Animal; Do | 2006 |
ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Blotting, Western; Corpus Striatum; Disease Models, | 2006 |
Serotonin 2A receptor antagonist treatment reduces dopamine D1 receptor-mediated rotational behavior but not L-DOPA-induced abnormal involuntary movements in the unilateral dopamine-depleted rat.
Topics: Analysis of Variance; Animals; Behavior, Animal; Chromatography, High Pressure Liquid; Dopamine; Dop | 2006 |
Coadministration of entacapone with levodopa attenuates the severity of dyskinesias in hemiparkinsonian rats.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Catechols; Disease Models, Animal; Drug Therapy | 2006 |
Neuroprotective and neurorescue effect of black tea extract in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Topics: Animals; Antioxidants; Brain; Cell Survival; Corpus Striatum; Cytoprotection; Disease Models, Animal | 2006 |
Reversion of levodopa-induced motor fluctuations by the A2A antagonist CSC is associated with an increase in striatal preprodynorphin mRNA expression in 6-OHDA-lesioned rats.
Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Adenosine; | 2006 |
Increased slow oscillatory activity in substantia nigra pars reticulata triggers abnormal involuntary movements in the 6-OHDA-lesioned rat in the presence of excessive extracellular striatal dopamine.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Animals; Behavior, Animal; Chromatography, High P | 2006 |
Effects of group I metabotropic glutamate receptors blockade in experimental models of Parkinson's disease.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Behavior, Animal; Catalepsy; Disease Models, An | 2006 |
L-DOPA-induced dyskinesia in adult rats with a unilateral 6-OHDA lesion of dopamine neurons is paralleled by increased c-fos gene expression in the subthalamic nucleus.
Topics: Animals; Autoradiography; Behavior, Animal; Dopamine; Dopamine Agents; Dopamine Uptake Inhibitors; D | 2006 |
Chronic high-frequency stimulation of the subthalamic nucleus and L-DOPA treatment in experimental parkinsonism: effects on motor behaviour and striatal glutamate transmission.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Dose-Response Relationship, | 2006 |
Effects of desensitized nicotinic receptors on rotational behavior in a 6-hydroxydopamine model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Brain; Disease Models, Animal; Dopamine Agonists; D | 2007 |
The differential effects of 5-HT(1A) receptor stimulation on dopamine receptor-mediated abnormal involuntary movements and rotations in the primed hemiparkinsonian rat.
Topics: Adrenergic Agents; Analysis of Variance; Animals; Behavior, Animal; Biogenic Monoamines; Chromatogra | 2007 |
RGS9-2 negatively modulates L-3,4-dihydroxyphenylalanine-induced dyskinesia in experimental Parkinson's disease.
Topics: Analysis of Variance; Animals; Behavior, Animal; Corpus Striatum; Dihydroxyphenylalanine; Disease Mo | 2007 |